Combigene AB (COMBI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Combigene AB (COMBI) has a cash flow conversion efficiency ratio of -0.087x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.23 Million ≈ $-670.56K USD) by net assets (Skr71.58 Million ≈ $7.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Combigene AB - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Combigene AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Combigene AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Combigene AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Combigene AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VIA OPTRONICS AG SP.ADS/1
F:5UU1
|
N/A |
|
Brikor Ltd
JSE:BIK
|
0.055x |
|
Tianci International, Inc. Common Stock
NASDAQ:CIIT
|
-0.369x |
|
Innity Corporation Bhd
KLSE:0147
|
-0.154x |
|
Astrotech Corp
NASDAQ:ASTC
|
-0.228x |
|
ROKMASTER Resources Corp
V:RKR
|
0.128x |
|
Thunderstruck Resources Ltd
V:AWE
|
-0.004x |
|
Prophecy International Holdings Ltd
AU:PRO
|
-2.309x |
Annual Cash Flow Conversion Efficiency for Combigene AB (2012–2024)
The table below shows the annual cash flow conversion efficiency of Combigene AB from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see COMBI stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr71.58 Million ≈ $7.70 Million |
Skr-29.95 Million ≈ $-3.22 Million |
-0.418x | -59.46% |
| 2023-12-31 | Skr116.46 Million ≈ $12.53 Million |
Skr-30.56 Million ≈ $-3.29 Million |
-0.262x | -139.51% |
| 2022-12-31 | Skr152.12 Million ≈ $16.37 Million |
Skr-16.67 Million ≈ $-1.79 Million |
-0.110x | -178.41% |
| 2021-12-31 | Skr158.28 Million ≈ $17.03 Million |
Skr22.11 Million ≈ $2.38 Million |
0.140x | +126.03% |
| 2020-12-31 | Skr71.43 Million ≈ $7.69 Million |
Skr-38.35 Million ≈ $-4.13 Million |
-0.537x | +49.55% |
| 2019-12-31 | Skr20.30 Million ≈ $2.19 Million |
Skr-21.60 Million ≈ $-2.33 Million |
-1.064x | -9662.78% |
| 2018-12-31 | Skr20.46 Million ≈ $2.20 Million |
Skr227.60K ≈ $24.49K |
0.011x | +100.76% |
| 2017-12-31 | Skr6.51 Million ≈ $700.81K |
Skr-9.53 Million ≈ $-1.03 Million |
-1.463x | +32.24% |
| 2016-12-31 | Skr4.08 Million ≈ $439.02K |
Skr-8.81 Million ≈ $-947.94K |
-2.159x | -252.65% |
| 2015-12-31 | Skr10.27 Million ≈ $1.10 Million |
Skr-6.29 Million ≈ $-676.42K |
-0.612x | -458.89% |
| 2014-12-31 | Skr5.67 Million ≈ $609.68K |
Skr-620.67K ≈ $-66.79K |
-0.110x | +75.90% |
| 2013-12-31 | Skr598.60K ≈ $64.42K |
Skr-272.15K ≈ $-29.29K |
-0.455x | -328.90% |
| 2012-12-31 | Skr298.09K ≈ $32.08K |
Skr59.21K ≈ $6.37K |
0.199x | -- |
About Combigene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The… Read more